Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune
system from rejecting the donor's stem cells when they do not exactly match the patient's
blood. The donated stem cells may replace the patient's immune cells and help destroy any
remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a
donor can also make an immune response against the body's normal cells. Giving antithymocyte
globulin before transplant and cyclosporine and mycophenolate mofetil before and after
transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well giving antithymocyte globulin together with
clofarabine and rituximab works in treating patients after an unsuccessful stem cell
transplant.